PMSA Global Summit 2023

J+D were proud to be presenting as part of the PMSA 2023 agenda boasting speakers from some of the top pharma including Merck, Boehringer Ingelheim, Novartis and AstraZeneca.

J+D CEO, David James was joined by Stefano Driussi, our Head of Software Engineering on the second day of the event to present on The Implications and Applications of AI and ML in Pharma Forecasting. 

In this talk, we delved into the implications and applications of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical forecasting. The pharmaceutical industry is already witnessing the critical role played by AI and ML in various areas such as drug discovery, drug manufacturing, diagnostic assistance, and optimizing medical treatment processes. However, understanding the impact of these technologies on forecasting requires exploration of both their potential application in the forecasting process and the broader implications of an AI revolution on the industry’s structure and the evolution of diseases.

Image credit: Pharmaceutical Management Science Association (PMSA) –

Following the opening reception the evening before, the 2 day summit opened on Wednesday morning with keynote speaker Suhail Alam, Head of Data and Analytics Novartis IM International.

With presentations, panel discussions and round table talks delivering an exciting agenda covering AI/Machine Learning, Next Generation Analytics, Omnichannel Customer Experience and Medical Intelligence, this event met its promises to be an interesting learning and networking experience.

About PMSA

As the thought leaders in pharmaceutical management science, PMSA is in a unique position to facilitate the sharing of ideas with our peers in Europe, the second largest commercial market in the world. Their knowledge, techniques and experiences are also an invaluable resource.

more insights

Our Pharmaceutical Forecasting Predictions for 2024

As the pharmaceutical industry contends with growing financial pressures, we examine its strategic outlook for 2024. How does the sector intend to align with projected commercial objectives while continuing to meet patient needs and what are the implications for forecasting teams?

Read more >